文献速递其他结缔组织病

维布妥昔单抗治疗难治性弥漫性皮肤型系统性硬化症皮肤受累的开放标签试验

Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项II期概念验证、单中心、开放标签、单臂、研究者发起的试验纳入11例弥漫性皮肤型系统性硬化症(dcSSc)患者,静脉给予维布妥昔单抗0.6 mg/kg每3周一次共45周。第48周mRSS平均下降11.3(95%CI 6.9, 15.8;P=0.001),意向治疗分析中7/11例mRSS下降≥8,达到主要终点,未见归因于维布妥昔单抗的严重不良事件。

要点

  • 第48周mRSS平均下降11.3(95%CI 6.9, 15.8;P=0.001),意向治疗分析中7/11例下降≥8。
  • 用力肺活量百分比平均增加7.8%(标准差12.5)。
  • dcSSc综合应答指数(CRISS)提示有益的治疗效应(86%≥0.6)。

核心结论

  • 在dcSSc中,维布妥昔单抗改善了皮肤和用力肺活量,且无安全性顾虑。
  • 作者认为需要一项安慰剂对照试验来证实这些初步发现。

研究设计与样本

  • II期概念验证、单中心、开放标签、单臂、研究者发起的试验。
  • 纳入年龄≥18岁、dcSSc、mRSS≥15且距首个非雷诺症状<5年和/或尽管免疫抑制治疗皮肤仍恶化的患者。
  • 静脉给予维布妥昔单抗0.6 mg/kg每3周一次,共45周。
  • 主要终点为第48周mRSS下降≥8分。
  • 11例患者接受治疗,9例完成研究。

主要发现

  • 第48周mRSS平均下降11.3(95%CI 6.9, 15.8;P=0.001)。
  • 意向治疗分析中7/11例mRSS下降≥8,达到主要终点。
  • 用力肺活量百分比平均增加7.8%(标准差12.5)。
  • dcSSc综合应答指数(CRISS)提示有益的治疗效应(86%≥0.6)。
  • 大多数不良事件为轻度,无归因于维布妥昔单抗的严重不良事件。

关键数值与推荐

  • 主要终点:第48周mRSS下降≥8分。
  • 给药方案:维布妥昔单抗0.6 mg/kg静脉注射,每3周一次,共45周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为单中心、开放标签、单臂试验,样本量为11例。
  • 作者结论指出需要一项安慰剂对照试验来证实这些初步发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc). METHODS: This phase II proof-of-concept, single centre, open-label, single arm, investigator-initiated trial included patients ≥18 years, with dcSSc, modified Rodnan skin score (mRSS) ≥15 with <5 years since the first non-Raynaud's symptom and/or skin worsening despite immunosuppression who were treated with intravenous brentuximab vedotin 0.6 mg/kg q3 weeks for 45 weeks. The primary end point was a decrease in mRSS of ≥8 points at 48 weeks. RESULTS: Eleven patients were treated with brentuximab vedotin, with nine completing the study. The mean mRSS reduction at week 48 was 11.3 (95% CI 6.9, 15.8; P = 0.001), meeting the primary end point in the intention to treat analysis (7/11 had a decrease in mRSS ≥8). The % forced vital capacity increased by 7.8% (12.5). The Composite Response Index in dcSSc (CRISS) suggested a beneficial treatment effect (86% ≥0.6). Most adverse events were mild. No SAEs were attributed to brentuximab vedotin. CONCLUSION: In dcSSc, brentuximab vedotin improved skin and FVC without safety concerns. A placebo-controlled trial is warranted to corroborate these initial findings. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03198689.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fernández-Codina A, Nevskaya T, Baron M, et al. Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial. Rheumatology (Oxford). 2025. PMID: 38652570. doi:10.1093/rheumatology/keae235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。